We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MorphoSys and Xencor Initiate Phase 1 Study of Anti-CD19 Antibody in Chronic Lymphocytic Leukemia
News

MorphoSys and Xencor Initiate Phase 1 Study of Anti-CD19 Antibody in Chronic Lymphocytic Leukemia

MorphoSys and Xencor Initiate Phase 1 Study of Anti-CD19 Antibody in Chronic Lymphocytic Leukemia
News

MorphoSys and Xencor Initiate Phase 1 Study of Anti-CD19 Antibody in Chronic Lymphocytic Leukemia

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MorphoSys and Xencor Initiate Phase 1 Study of Anti-CD19 Antibody in Chronic Lymphocytic Leukemia"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MorphoSys AG and Xencor, Inc. have announced that they have initiated Phase 1 testing of MOR208 (XmAb®5574), and the first patient has been dosed.

MOR208 (XmAb5574) is a potent monoclonal anti-CD19 antibody to which MorphoSys recently gained worldwide access via an exclusive license and collaboration agreement with Xencor. The trial is designed to assess the drug's safety, tolerability, pharmacokinetic profile and preliminary anti-tumor activity in chronic lymphocytic leukemia (CLL) patients.

The open-label, multi-dose, single-arm, dose-escalation study is estimated to enroll 30 patients suffering from relapsed or refractory CLL. More information on the trial can be found by searching for XmAb5574 at http://www.clinicaltrials.gov.

"With MOR208, our second proprietary compound enters clinical trials in addition to currently ten programs being developed in the clinic by our partners", commented Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG. "CD19 represents a particularly attractive immunotherapy target for cancers of lymphoid origin, due to its high expression levels on non-Hodgkin's lymphomas and B-cell leukemias such as chronic lymphocytic leukemia."

"This is the fourth high ADCC antibody based on our XmAb technology that has reached the clinic, demonstrating the tremendous progress our optimization technologies have made in producing next-generation biological drugs," said Bassil Dahiyat, Ph.D., CEO of Xencor. "We'll be collaborating with our new partner MorphoSys through Phase 1, and are sure that their antibody expertise and product development capabilities will help accelerate the compound's clinical progress."

In preclinical studies, MOR208 (XmAb5574) was well tolerated at various dose levels, elicited immediate and sustained B-cell depletion, and showed strong anti-tumor potency, anti-proliferative and apoptotic activity. B-cell malignancies, such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia afflict more than one hundred and fifty thousand patients in the seven major markets each year. CD19 is expressed more broadly and earlier in B-cell development than CD20, the target of the marketed cancer drug Rituxan®, therefore potentially allowing for an even broader use of MOR208 (XmAb5574) as compared to Rituxan.
Advertisement